
The Competition and Markets Authority (CMA) of the United Kingdom confirmed it is moving forward with a more in-depth investigation of Microsoft’s Activision Blizzard acquisition. Sony has responded, praising the regulator’s decision.
The CMA announced on Thursday that it has referred the Microsoft-Activision Blizzard deal for an in-depth investigation, which the regulator calls a Phase 2 inquiry.
UK’s market competition watchdog released its initial findings last Sept. 1, saying the $68.7 billion deal could lead to a “substantial lessening of competition.” According to CMA’s rules, Microsoft and Activision Blizzard would have to present remedies within five working days to prove that their deal will not negatively impact the video game market in the UK.
In its reference decision published on Thursday, the CMA said it was informed last Sept. 6 that Microsoft chose not to provide remedies to the regulator’s concerns. This corroborated a report from the Financial Timeswith sources that claimed Microsoft did not expect the CMA to accept any commitments that would have prevented a Phase 2 inquiry. Per the timetable CMA posted, the in-depth investigation could run through March 2023.
Sony, one of the companies most vocal about the acquisition, praised the CMA for its decision. “By giving Microsoft control of Activision games like ‘Call of Duty,’ this deal would have major negative implications for gamers and the future of the gaming industry,” the company told GamesIndustry.biz. “We want to guarantee PlayStation gamers continue to have the highest quality gaming experience, and we appreciate the CMA’s focus on protecting gamers.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas